Search results for " Type 1"

showing 10 items of 430 documents

Bone Mineral Density and Bone Metabolism in Diabetes Mellitus

1998

The effect of diabetes mellitus on bone metabolism and bone mineral density is discussed controversially. Diabetes mellitus due to an autoimmune process seems to be associated with low turnover osteopenia either in the animal model or in children and adolescents. A number of factors are discussed as being involved, but in this age group clinical symptoms are missing. Adult patients of either sex with IDDM show a reduced bone mineral density when measured at peripheral sites such as the distal forearm or the femoral neck, diabetic complications such as neuropathy and microangiopathy seem to pronounce the deficit of bone mass. In these patients, osteopenia is accompanied by a high turnover si…

medicine.medical_specialtyBone densityEndocrinology Diabetes and MetabolismClinical BiochemistryOverweightBiochemistryBone and BonesBone remodelingEndocrinologyBone DensityDiabetes mellitusInternal medicinemedicineAnimalsHumansRats Inbred BBFemoral neckBone mineralbusiness.industryBiochemistry (medical)MicroangiopathyGeneral Medicinemedicine.diseaseRatsOsteopeniaDiabetes Mellitus Type 1Endocrinologymedicine.anatomical_structureDiabetes Mellitus Type 2Osteoporosismedicine.symptombusinessHormone and Metabolic Research
researchProduct

Special Considerations for Antihypertensive Agents in Dialysis Patients

2010

Hypertension is present in most patients with end-stage renal disease and likely contributes to the premature cardiovascular disease in dialysis patients. Previous practice guidelines have recommended that, in patients on chronic dialysis, blood pressure (BP) should be reduced below 130/80 mm Hg. This is based on opinions but not strong evidence, since no concrete information exists about which BP values should be the parameter to follow and which should be the target BP values. The majority of the antihypertensive agents can be used in this population, but the pharmacokinetics altered by the impaired kidney function and dialyzability influence the appropriate dosage as well as the time and…

medicine.medical_specialtyCardiotonic AgentsHypertension RenalCombination therapyMetabolic Clearance Ratemedicine.drug_classVasodilator Agentsmedicine.medical_treatmentAdrenergic beta-AntagonistsPopulationAngiotensin-Converting Enzyme InhibitorsCardiotonic AgentsRenal DialysisInternal medicinemedicineHumansDrug InteractionsDiureticseducationAntihypertensive drugAntihypertensive AgentsDialysisRandomized Controlled Trials as Topiceducation.field_of_studybusiness.industryHematologyGeneral MedicineCalcium Channel Blockersmedicine.diseaseEndocrinologyBlood pressureCardiovascular DiseasesNephrologyPractice Guidelines as TopicPolypharmacyKidney Failure ChronicDrug Therapy CombinationHemodialysisbusinessAngiotensin II Type 1 Receptor BlockersKidney diseaseBlood Purification
researchProduct

Comparative characteristics of older people with type 1 diabetes treated with continuous subcutaneous insulin infusion or insulin injection therapy :…

2019

Aim To compare clinical characteristics and outcomes in adults with type 1 diabetes aged ≥ 60 years using continuous subcutaneous insulin infusion (CSII) vs. insulin injection therapy. Further, to determine the percentage of older adults with type 1 diabetes using CSII. Research design and methods Retrospective study using data of the Diabetes Prospective Follow-up Registry (DPV). Including percentage CSII use from 2008 to 2018, and the characteristics of 9547 individuals extracted from the DPV in March 2019 (N = 1404 CSII; N = 8143 insulin injection therapy). Wilcoxon rank sum tests were used for continuous variables and chi-square tests for categorical variables to compare clinical charac…

medicine.medical_specialtyDiabetic ketoacidosisEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolism03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusInternal medicineDiabetes mellitus Type 1Internal MedicineMedicine030212 general & internal medicineddc:610ContraindicationDepression (differential diagnoses)AgedType 1 diabetesbusiness.industryInsulinCSIIDiabetes mellitus; TherapyDiabetes mellitus Typ 1Retrospective cohort studymedicine.diseaseInsulin infusion systems3. Good healthMicroalbuminuriaOlder peopleInsulinpumpebusinessAlter <60-90 Jahre>
researchProduct

Conduction velocity study in type 1 diabetic patients.

1989

The role of metabolic abnormalities in the development of diabetic neuropathy is controversial. To investigate the peripheral nerve function and the influence of hyperglycemia on nerve conduction in insulin-dependent diabetes, a one-year neurophysiological study was carried out in 30 type 1 diabetic patients ranging in age from 2-16 years. During the 12-month follow-up period the glycosylated hemoglobin determination, motor conduction velocity of the peroneal nerve and the motor and sensory conduction of the tibial nerve were assessed 3 times, at the beginning of the study and every 6 months thereafter. The sensory latency was found significantly delayed in these patients as compared with t…

medicine.medical_specialtyDiabetic neuropathyAdolescentNeural ConductionSensory systemNerve conduction velocityDiabetic NeuropathiesInternal medicineDiabetes mellitusElectroneuronographyReaction TimeMedicineHumansTibial nerveChildNeural Conductionbusiness.industryAge FactorsInfantGeneral Medicinemedicine.diseaseEndocrinologyDiabetes Mellitus Type 1NeurologyChild PreschoolCardiologyNeurology (clinical)HemoglobinbusinessActa neurologica Scandinavica
researchProduct

Transient chylomicronemia preceding the onset of insulin-dependent diabetes in a young girl with no humoral markers of islet autoimmunity

2004

OBJECTIVE: We investigated the possible causes of diabetes in a young child who presented with hyperglycemia associated with severe hypertriglyceridemia (&gt;166 mmol/l), hypercholesterolemia (&gt;38 mmol/l) and fasting chilomicrons. RESULTS: The patient did not have any of the HLA and autoantibody markers typically associated with type 1 diabetes. A glucose clamp failed to demonstrate insulin resistance (peripheral glucose utilization rate (M)=4.3 mg/kg per min) and there was no family history of type 2 diabetes or maturity onset diabetes in youth. Both fasting and stimulated C-peptide levels, including those in response to i.v. glucagon, were below the limit of detection. This is consiste…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismHypercholesterolemiaAutoimmunityType 2 diabeteschylomicronemia diabetes young girl autoimmunityGlucagonIslets of LangerhansLipoprotein lipase deficiencyEndocrinologyInsulin resistanceInternal medicineDiabetes mellitusChylomicronsmedicineHumansChildAutoantibodiesHypertriglyceridemiaType 1 diabetesC-Peptidebusiness.industryHypertriglyceridemiaFastingGeneral MedicineGlucose clamp techniqueGlucagonmedicine.diseaseLipoprotein LipaseDiabetes Mellitus Type 1EndocrinologyHyperglycemiaGlucose Clamp TechniqueFemalelipids (amino acids peptides and proteins)businessEuropean Journal of Endocrinology
researchProduct

Comment on: Comparative characteristics of older people with type 1 diabetes treated with continuous subcutaneous insulin infusion or insulin injecti…

2020

medicine.medical_specialtyEndocrinology Diabetes and MetabolismMEDLINEGermanEndocrinologyInsulin Infusion SystemsInternal medicineInternal MedicineMedicineHumansHypoglycemic AgentsInsulinRegistriesInsulin injectionAgedAged 80 and overType 1 diabetesbusiness.industrymedicine.diseaselanguage.human_languageSubcutaneous insulinDiabetes Mellitus Type 1AustrialanguagebusinessOlder peopleDiabetic medicine : a journal of the British Diabetic Association
researchProduct

Angiotensin II induces leukocyte-endothelial cell interactions in vivo via AT(1) and AT(2) receptor-mediated P-selectin upregulation.

2000

Background —Angiotensin II (Ang II) plays a critical role in the development of vascular lesions in hypertension, atherosclerosis, and several renal diseases. Because Ang II may contribute to the leukocyte recruitment associated with these pathological states, the aim of the present study was to assess the role of Ang II in leukocyte–endothelial cell interactions in vivo. Methods and Results —Intravital microscopy of the rat mesenteric postcapillary venules was used. Sixty minutes of superfusion with 1 nmol/L Ang II induced a significant increase in leukocyte rolling flux (83.8±20.7 versus 16.4±3.1 cells/min), adhesion (11.4±1.0 versus 0.8±0.5 cells/100 μm), and emigration (4.0±0.7 versus …

medicine.medical_specialtyEndotheliumPyridinesLeukocyte RollingCell CommunicationReceptor Angiotensin Type 2LosartanReceptor Angiotensin Type 1Rats Sprague-DawleyDownregulation and upregulationPhysiology (medical)Internal medicineCromolyn SodiummedicineLeukocytesAnimalsEndotheliumReceptorAngiotensin II receptor type 1Receptors Angiotensinbusiness.industryAngiotensin IIImidazolesFlow CytometryAngiotensin IIRatsUp-RegulationEndothelial stem cellP-Selectinmedicine.anatomical_structureEndocrinologyLosartanCardiology and Cardiovascular Medicinebusinessmedicine.drugCirculation
researchProduct

The effect of human proinsulin C-peptide on erythrocyte deformability in patients with Type I diabetes mellitus.

1999

Aims/hypothesis. In recent years, evidence has arisen that proinsulin C-peptide exerts biological effects especially on microcirculation, e. g. C-peptide has been shown to increase skin microcirculation in patients with Type I (insulin-dependent) diabetes mellitus and to activate endothelial nitric oxide synthase. This study aimed to investigate the influence of proinsulin C-peptide on erythrocyte deformability which was assessed by means of laser diffractoscopy. Methods. Blood samples from healthy control subjects (n = 10) and Type I diabetic patients (n = 15) completely deficient of C-peptide were analysed at shear stresses ranging from 0.3 to 30 Pa. Results. Erythrocyte deformability was…

medicine.medical_specialtyErythrocytesEndocrinology Diabetes and MetabolismProhormoneMicrocirculationBlood cellchemistry.chemical_compoundInternal medicineDiabetes mellitusErythrocyte DeformabilityInternal MedicineMedicineErythrocyte deformabilityHumansEnzyme InhibitorsOuabainProinsulinC-Peptidebusiness.industryC-peptideLasersmedicine.diseaseRed blood cellEndocrinologymedicine.anatomical_structureDiabetes Mellitus Type 1chemistrySodium-Potassium-Exchanging ATPasebusinessmedicine.drugDiabetologia
researchProduct

New Melanocortin 1 Receptor Binding Motif Based on the C-Terminal Sequence of ?-Melanocyte-Stimulating Hormone

2006

The C-terminal tripeptide of the alpha-melanocyte stimulating hormone (alpha-MSH11-13) possesses strong antiinflammatory activity without known cellular target. In order to better understand the structural requirements for function of such motif, we designed, synthesized and tested out Trp- and Tyr-containing analogues of the alpha-MSH11-13. Seven alpha-MSH11-13 analogues were synthesized and characterized for their binding to the melanocortin receptors recombinantly expressed in insect (Sf9) cells, infected with baculovirus carrying corresponding MC receptor DNA. We also tested these analogues on B16-F1 mouse melanoma cells endogenously expressing the MC1 receptor for binding and for abili…

medicine.medical_specialtyGrowth-hormone-releasing hormone receptorProtein ConformationAmino Acid MotifsMelanoma ExperimentalBiologyToxicologyBinding CompetitiveMiceThyrotropin-releasing hormone receptorInternal medicineChlorocebus aethiopsmedicineEnzyme-linked receptorAnimalsHumansACTH receptorMelanocyte-Stimulating HormonesReceptorPharmacologyGeneral MedicineMelanocortin 3 receptorCell biologyEndocrinologyCOS CellsEstrogen-related receptor gammaMelanocortinReceptor Melanocortin Type 1Basic &lt;html_ent glyph="@amp;" ascii="&amp;amp;"/&gt; Clinical Pharmacology &lt;html_ent glyph="@amp;" ascii="&amp;amp;"/&gt; Toxicology
researchProduct

In vivo antihypertensive mechanism of lactoferrin-derived peptides: Reversion of angiotensin I- and angiotensin II-induced hypertension in Wistar rats

2015

Novel peptides with antihypertensive effects in SHR rats have previously been identified in lactoferrin (LF) hydrolysates. To investigate their in vivo antihypertensive mechanism, we have assessed the blood pressure lowering effects of two of these LF-derived peptides (RPYL and DPYKLRP) in Wistar rats subjected to either angiotensin I- or angiotensin II-induced hypertension. Blood pressure was measured by the tail-cuff method, hypertension was induced by subcutaneous infusion of angiotensins, and then captopril, valsartan or LF-derived peptides orally administered. Angiotensin I- and angiotensin II-induced hypertension were reversed by captopril and valsartan, respectively. RPYL and DPYKLRP…

medicine.medical_specialtyMedicine (miscellaneous)Lactoferrin-derived peptidesPharmacologyWistar ratAntihypertensive peptidesInternal medicineRenin–angiotensin systemMedicineTX341-641Angiotensin-induced hypertensionNutrition and DieteticsAngiotensin II receptor type 1biologyNutrition. Foods and food supplybusiness.industryCaptoprilAngiotensin-converting enzymeAngiotensin IIBlood pressureEndocrinologyValsartanbiology.proteinRenin angiotensin systemmedicine.symptombusinessVasoconstrictionFood Sciencemedicine.drugIn vivo ACE inhibition
researchProduct